Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [41] Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
    Rajan, Arun
    Kim, Chul
    Heery, Christopher R.
    Guha, Udayan
    Gulley, James L.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (09) : 2219 - 2231
  • [42] Home anti-PD1 immunotherapy for melanoma: results of a patient and nursing satisfaction survey
    Truong, Thu Thao
    Lapassat, Marie
    Belbezier, Aude
    Leccia, Marie-Therese
    Mouret, Stephane
    Lemoigne, Aude
    Charles, Julie
    Trabelsi, Sabiha
    EUROPEAN JOURNAL OF DERMATOLOGY, 2025, 35 (01) : 31 - 37
  • [43] Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1
    Liu, Nian
    Zhang, Jianglin
    Yan, Mingjie
    Chen, Lihui
    Wu, Jie
    Tao, Qian
    Yan, Bei
    Chen, Xiang
    Peng, Cong
    CELL DEATH & DISEASE, 2023, 14 (02)
  • [44] Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors
    Gomes, Jessica Ribeiro
    Schmerling, Rafael A.
    Haddad, Carolina K.
    Racy, Douglas J.
    Ferrigno, Robson
    Gil, Erlon
    Zanuncio, Pedro
    Buzaid, Antonio C.
    JOURNAL OF IMMUNOTHERAPY, 2016, 39 (09) : 367 - 372
  • [45] Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
    Fujimura, Taku
    Kambayashi, Yumi
    Ohuchi, Kentaro
    Amagai, Ryo
    Sato, Yota
    Tanita, Kayo
    Hashimoto, Akira
    Aiba, Setsuya
    CASE REPORTS IN ONCOLOGY, 2020, 13 (01): : 271 - 275
  • [46] Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
    Rose, April A. N.
    Armstrong, Susan M.
    Hogg, David
    Butler, Marcus O.
    Saibil, Samuel D.
    Arteaga, Diana P.
    Muniz, Thiago Pimentel
    Kelly, Deirdre
    Ghazarian, Danny
    King, Ian
    Kamil, Zaid Saeed
    Ross, Kendra
    Spreafico, Anna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [47] The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma
    Coen, Oliver
    Corrie, Pippa
    Marshall, Helen
    Plummer, Ruth
    Ottensmeier, Christian
    Hook, Jane
    Bell, Sue
    Sagoo, Gurdeep S.
    Meads, David
    Bestall, Janine
    Velikova, Galina
    Gallagher, Ferdia A.
    Smith, Alexandra
    Howard, Helen
    Mason, Ellen
    Katona, Eszter
    Silva, Shobha
    Collinson, Michelle
    Rodwell, Simon
    Danson, Sarah
    BMC CANCER, 2021, 21 (01)
  • [48] Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus A case report
    Inadomi, Kyoko
    Kumagai, Hozumi
    Arita, Shuji
    Tsuruta, Nobuhiro
    Takayoshi, Kotoe
    Mishima, Koji
    Ota, Shun-Ichiro
    Tanaka, Mamoru
    Okumura, Yuta
    Sagara, Kosuke
    Nio, Kenta
    Nakano, Michitaka
    Uchi, Hiroshi
    Yamamoto, Hidetaka
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Niiro, Hiroaki
    Oda, Yoshinao
    Akashi, Koichi
    Baba, Eishi
    MEDICINE, 2016, 95 (29)
  • [49] Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
    Prasad, Vinay
    Kaestner, Victoria
    SEMINARS IN ONCOLOGY, 2017, 44 (02) : 132 - 135
  • [50] CRP and soluble CTLA4 are determinants of anti-PD1 resistance in gastrointestinal cancer
    Oshima, Kotoe
    Shoji, Hirokazu
    Boku, Narikazu
    Hirano, Hidekazu
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Kudo-Saito, Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (03): : 1174 - 1189
12345